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Abstract
Background Aromatase inhibitors such as anastrozole and
letrozole are highly effective suppressants of estrogen synthesis
in postmenopausal women and are the most effective endocrine
treatments for hormone receptor positive breast cancer in such
women. Little is known of the molecular effects of these agents
on human breast carcinomas in vivo.
Methods We randomly assigned primary estrogen receptor
positive breast cancer patients to treatment with anastrozole or
letrozole for 2 weeks before surgery. Expression profiling using
cDNA arrays was conducted on pretreatment and post-
treatment biopsies. Sample pairs from 34 patients provided
sufficient RNA for analysis.
Results Profound changes in gene expression were seen with
both aromatase inhibitors, including many classical estrogen-
dependent genes such as TFF1, CCND1, PDZK1 and AGR2,
but also many other genes that are likely to represent secondary
responses; decrease in the expression of proliferation-related
genes were particularly prominent. Many upregulated genes are
involved in extracellular matrix remodelling, including collagens
and members of the small leucine-rich proteoglycan family
(LUM, DCN, and ASPN). No significant differences were seen
between letrozole and anastrozole in terms of molecular effects.
The gene changes were integrated into a Global Index of
Dependence on Estrogen (GIDE), which enumerates the genes
changing by at least twofold with therapy. The GIDE varied
markedly between tumours and related significantly to
pretreatment levels of HER2 and changes in
immunohistochemically detected Ki67.
Conclusion Our findings identify the transcriptional signatures
associated with aromatase inhibitor treatment of primary breast
tumours. Larger datasets using this approach should enable
identification of estrogen-dependent molecular changes, which
are the determinants of benefit or resistance to endocrine
therapy.
Introduction
Approaching 80% of human breast carcinomas express estro-
gen receptor (ER)-α protein at clinically significant levels and
are considered ER positive. Estrogen deprivation, or antago-
nism, is an effective treatment for many but not all patients with
such tumours. The selective ER modifier tamoxifen has been
the predominant treatment for the past two decades and
improves survival in ER-positive patients receiving this as adju-
vant therapy after surgery [1]. However, in postmenopausal
women aromatase inhibition with the nonsteroidal inhibitors
anastrozole and letrozole has now been shown to be more
effective than tamoxifen as adjuvant therapy [2]. Letrozole and
anastrozole are highly specific for the aromatase enzyme and
inhibit whole body aromatization by 99% and 97%,
AI = aromatase inhibitor; ER = estrogen receptor; ECM = extracellular matrix; GIDE = Global Index of Dependence on Estrogen; PCR = polymerase 
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respectively [3]. Aromatase inhibitors (AIs) therefore confer
highly selective and essentially complete withdrawal of estro-
gen in postmenopausal patients.
Proliferation of malignant cells, as measured by expression of
the nuclear antigen Ki67, is reduced in more than 90% of ER-
positive primary breast carcinomas by treatment with AIs [4,5].
This suggests that almost all ER-positive tumours derive some
proliferative stimulus from estrogen and may be considered
hormone responsive; in some patients, however, this effect
may be only modest. We recently found that the difference in
the change in Ki67 after 2 weeks of treatment with anastrozole
or tamoxifen, or the two drugs in combination was predictive
of relative recurrence-free survival in a parallel adjuvant trial of
the same treatments [6]. Additionally, Ki67 levels after 2
weeks of treatment significantly correlated with recurrence-
free survival in the same patients in the presurgical study [7].
Both of these findings support the validity of short-term
changes in Ki67 as an intermediate marker of the clinical effec-
tiveness of endocrine therapy. It seems likely, however, that
Ki67 is an imperfect marker of proliferation and that changes
in gene expression other than those related to proliferation
may be involved in determining the clinical effectiveness of
estrogen deprivation.
Transcriptional profiling of estrogen responses in ER-positive
human breast cancer cell lines and model systems in vitro
leads to changes in the transcription of large numbers of
genes [8,9], but very little is known of these effects in vivo or
how these effects vary between tumours and whether these
molecular changes fully encompass the determinants of clini-
cal response. Biopsy of tumours before and during presurgical
treatment with an AI allows the study of estrogen-dependent
effects across a range of ER-positive breast carcinomas in
situ.
We therefore evaluated the effects of estrogen deprivation
with letrozole or anastrozole on Ki67 expression and transcrip-
tional profiles in ER-positive breast carcinomas in vivo. Such
an approach might provide insights into the mechanisms of
clinical benefit and allow the development of a predictor of that
benefit.
Our specific aims in the present study were as follows: to
determine whether there is a significant difference between
letrozole and anastrozole in terms of change in Ki67 (reported
elsewhere) and changes in gene transcription; to identify the
genes that change with aromatase inhibition and to integrate
these as a Global Index of Dependence on Estrogen (GIDE);
to assess how the most prominent gene changes relate to
those reported in vitro with estrogen stimulation; and to deter-
mine the relationship between the GIDE and previously
described putative determinants of benefit from endocrine
therapy such as HER2 and Ki67 expression.
Materials and methods
Patient samples
Postmenopausal patients with primary ER-positive (Allred
scores 2 to 8; note that scores of 2 are conventionally
regarded as ER negative [10]) breast cancer were randomly
assigned to presurgical treatment for 2 weeks with letrozole
(2.5 mg/day orally) or anastrozole (1 mg/day orally). Multiple
core-cut biopsies were taken with a 14-guage needle before
treatment and at surgery from 54 patients, and were either
immediately frozen in liquid nitrogen for RNA analysis or were
fixed in neutral buffered formalin for immunohistochemistry.
RNA from each frozen biopsy was extracted using Trizol (Invit-
rogen, Paisley, UK), in accordance with the manufacturer's
instructions.
Microarray hybridizations
Total RNA integrity was confirmed on an Agilent 2100 BioAn-
alyser (Agilent Technologies, South Queensferry, West
Lothian, UK) before linear T7 amplification using a RiboAmp kit
(Arcturus/Molecular Devices Corporation Sunnyvcale, CA,
USA). Amplified aRNA (4 μg) was labeled with either cy3 or
cy5 and hybridized to Breakthrough 17K cDNA microarrays in
replicate dye swap hybridizations, as previously described
[11]. The Breakthrough 17K microarray platform and all pri-
mary microarray data have been submitted to Array Express
(ArrayExpress submission number E-TABM-180). Annotation
of the Breakthrough 17K cDNA microarray based on build
189 of Unigene is provided as Additional file 6.
Analysis of microarray data
Expression values from spots with hybridization artefacts or
extremely low intensities were flagged in Genepix 5.1 (Axon
Instruments/Molecular Devices Corporation Sunnyvcale, CA,
USA) and then converted to missing values and removed from
the analysis. The raw intensity values were then converted to
log2 ratios of sample to reference (M values) and log2 average
spot intensity (A values) for all subsequent pre-processing and
analysis. The loess local regression function was used to
remove biases resulting from the combined effect of spot
intensity and the row group to which the spot belonged, and
then to remove the more global bias across the slide. A quan-
tile filter was used to remove data that had average intensity or
A values below the 25th percentile in 60% or more of the
hybridizations. The M values for each hybridization were
rescaled so as to remove the relationship between increasing
dispersion of M values with increasing dispersion of A values
across the hybridisations. This latter transformation did not
involve extensive rescaling of the data and although it clarified
the relationships found in this study, these were all apparent
without this step. The replicate dye swap hybridizations were
then averaged. This left 14,024 genes that were used for
paired (pre/post) differential gene expression analysis using
SAM version 2.21 [12]. In order to focus on the more extensive
gene fluctuations between samples, further reductions in the
number of genes used for some analyses were based onAvailable online http://breast-cancer-research.com/content/9/3/R37
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filtering out genes with low inter-sample variation. We used
the interquartile range as a robust estimate of gene variation
and used a stringent threshold at interquartile range = 0.75
(2,418 genes remaining).
In order to map the gross phenotypic changes across the sam-
ples, the following supervised analysis was chosen. A core set
of genes was selected using the weighted Kolmogorov-Smir-
nov statistic because of its robustness and flexibility. The max-
imum number of genes (421) that gave minimum leave-one-
out cross-validation in separating pretreatment from post-
treatment samples using the k-nearest-neighbor algorithm (k =
7) was identified, and these genes were retained. Agglomera-
tive clustering (see below) was used to separate the 421
selected genes into 10 clusters of co-regulated genes. Each
cluster was then represented by the average M value of its
genes for each sample (metagene) following centering and
rescaling across samples. All clustering used the flexible β
agglomerative clustering algorithm with a correlation distance
measure for both genes and arrays. Clustering heat maps
were produced with Java Treeview 1.0.12 software. Correla-
tions were performed with Spearman rank or Pearson
correlations.
Immunohistochemistry
Conventional immunohistochemistry was performed on each
biopsy using antibodies for ER-α clone 6F11 (Novocatsra
Laboratories, Newcastle. upon Tyne, UK), progesterone
receptor (PgR) clone PgR 636 (Dako Ltd., Ely, Cambridge-
shire, UK), and KI67 clone MIB-1 (DAKO), in accordance with
the manufacturers' instructions.
ER and PgR immunohistochemistry were quantitated accord-
ing to Allred score [10]. Ki67 immunohistochemistry is
reported as the number of positive cells among 1,000 malig-
nant cells counted and is expressed as a percentage.
Real-time PCR
Quantitative real-time PCR was conducted in five genes of
interest (CCND1, PDZK1, FAS, TFF1, and MAN1A1). Total
RNA from the same RNA preparations as used for microarray
analysis was reverse transcribed using random primers and
Superscript III (Invitrogen), in accordance with the manufac-
turer's instructions. A reverse transcription negative control
was included to account for any genomic DNA contamination.
cDNA samples were subjected to quantitative PCR using Taq-
man® (Applied Biosystems, Warrington, UK) on an ABI Prism
7900 HT with primers designed by Primer Express, or Quant-
itect SYBR green (Qiagen, Crawley, West Sussex, UK) on an
Opticon Monitor 2 with primers designed by Primer 3 in two
different laboratories. Primer sequences are shown in Addi-
tional file 1. Pretreatment/post-treatment changes were esti-
mated after normalization using the geometric mean of the two
reference genes that had been shown to be unchanged in
expression during treatment with AIs (TBP and KIAA0674).
Results
RNA of sufficient quality and quantity was obtained from 34
pretreatment/post-treatment pairs of samples. The following
findings refer solely to those samples. Patient clinical informa-
tion is summarized in Additional file 2.
The samples were clustered to determine whether pretreat-
ment and post-treatment biopsies aggregated together as
nearest neighbors in clustering dendrograms. Half of pre/post
biopsy pairs were found to co-aggregate whether based on all
14,034 measured genes (17/34) or the 2,418 genes remain-
ing following filtering to retain the most variable genes (18/34).
Similar proportions of co-aggregating pairs were also identi-
fied using other algorithms (for instance, complete linkage and
group average linkage; data not shown). Separation of paired
biopsies in this analysis contrasts with other studies in which
the differences in gene expression among breast tumours is
far greater than that observed as a result of treatment with
chemotherapeutic agents [11,13].
A heat map diagram from clustering of the 2,418 most variable
genes among the 68 biopsies is shown in Figure 1. Clusters
of genes containing some of the most important known mark-
ers of breast tumour phenotype are shown in greater detail:
ESR1 (Figure 1a), MKI67 (Figure 1b), ERBB2 (Figure 1c),
and  TFF1  (Figure 1d). Levels of ESR1  and  ERBB2  gene
expression were inversely correlated in these samples (r = -
0.57, P = 0.0005, Pearson correlation), as has been shown in
many other studies of breast tumours. The samples with the
lowest ESR1 or high ERBB2 invariably had pre/post biopsy
pairs that co-aggregated as nearest neighbours and
accounted for more than half (11/17) of the co-aggregating
pairs. The ERBB2 cluster contained several genes that are
present in the ERBB2 amplicon on chromosome 17q12-21,
including GRB7,  THRAP4, and STARD3, and were highly
over-expressed in the four HER2 amplified cases. Data files for
Java Treeview are provided as supplementary information
(Additional files 7, 8, 9, 10).
To summarize the effects of estrogen deprivation on gene
expression, we have derived a Global Index of Dependence on
Estrogen (GIDE). This index was defined as the number of
genes changing by at least twofold between each pair of biop-
sies irrespective of the direction of change. This index corre-
lated positively with change in the proliferation marker Ki67
(Spearman rank rho = 0.533, P = 0.0022; Figure 2a) and neg-
atively with the expression of ERBB2 (Spearman rank rho = -
0.381, P = 0.0282; Figure 2b). Although no patients with a
high GIDE were among the lowest in terms of ESR1 expres-
sion, overall there was not a significant correlation between
the two. A complete summary of GIDE data is provided in
Additional file 3.
The primary end-point of the study was the reduction in tumour
proliferation measured as the change in the biomarker Ki67 byBreast Cancer Research    Vol 9 No 3    Mackay et al.
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conventional immunohistochemistry. The relationship between
change in Ki67 immunohistochemistry and microarray expres-
sion of ESR1 and ERBB2 is shown in Figure 2c,d. Tumours
expressing low levels of ER or high levels of ERBB2 exhibited
less reduction in Ki67 staining following AI treatment.
Correlations of the GIDE with immunohistochemical measure-
ments of ER and PgR (Allred score) are shown in Figure 2e,f.
In these samples there was a significant correlation of GIDE
with pretreatment ER staining but not with that of PgR. There
was no significant difference between letrozole and anastro-
zole in their effects on the GIDE or on Ki67, confirming the
result for the whole patient set [14].
A paired SAM statistical analysis identified 1,395 genes that
were upregulated and 1,264 genes that were downregulated
by AI treatment using a local false discovery rate threshold of
1%. Significantly changing genes were then ranked according
to their average fold change; the top 40 downregulated genes
are listed in Table 1 and the top 40 upregulated genes are
listed in Table 2 (the complete list is shown in Additional file
4). The most consistently downregulated genes included
TFF1, PDZK1, AGR2, TFF3, STC2, and CCND1. The most
consistently upregulated genes included LUM,  CALD1,
ASPN, DCN, PDGFRA, VIM, SPARC, MAN1A1, and FAS.
Quantitative real-time PCR confirmed significant upregulation
of MAN1A1 and FAS (P < 0.05 for each) and downregulation
of TFF1, PDZK1, and CCND1 (P < 0.01, P < 0.001 and P <
0.001, respectively; data not shown). The complete list of
upregulated and downregulated genes was subjected to
Gene Ontology analysis using Onto-Express and Pathway
Express [15].
The change in expression in some of these key index genes in
individual patients is shown in Figure 3; the change in Ki67
immunohistochemistry is also shown for comparison. The
majority of tumours exhibit large changes in expression of
these genes. However, changes in the expression of individual
estrogen-responsive genes did not clearly identify tumours
with a poor antiproliferative response. Different subsets of
tumours exhibited the largest or smallest responses in expres-
sion changes for each different gene.
To map the gross phenotypic changes of the tumours in
response to AI treatment relative to their initial states, we
selected a core set of 421 genes that distinguished pretreat-
ment from post-treatment biopies (see Materials and methods,
above). These were used to produce the heat map shown in
Figure 4 and separated the biopsies into predominantly pre-
treatment and post-treatment arms. Three of the four HER2
amplified cases had pretreatment profiles that segregated in
the post-treatment arm (216, 228, and 64). The fourth (203)
was the only case that expressed high levels of both ESR1
and ERBB2. Seven of the eight pretreatment biopsies that
were incorrectly grouped included seven of the 10 biopsies
with the lowest pretreatment expression of ESR1 (217, 216,
228, 138, 39, 64, and P3). Data files for Java Treeview are pro-
vided as supplementary information (Additional files 11, 12,
13, 14).
Figure 1
Heatmap of unsupervised clustering of pretreatment and post-treatment biopsies Heatmap of unsupervised clustering of pretreatment and post-treatment biopsies. A heatmap of the unsupervised clustering of the 34 pretreatment 
and post-treatment samples (labeled A and B respectively) using 2,418 of the most variable genes is shown. The entire heatmap is shown in minia-
ture on the left. Clusters containing the genes (a) ESR1, (b) MKI67, (c) ERBB2 and (d) TFF1 are shown in detail. Out of 34 pairs of biopsies, 18 
co-aggregated at the first or second level in the sample dendrogram.Available online http://breast-cancer-research.com/content/9/3/R37
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Figure 2
Comparison of GIDE score and change in Ki67 immunohistochemistry with ESR1 and ERBB2 expression Comparison of GIDE score and change in Ki67 immunohistochemistry with ESR1 and ERBB2 expression. (a) Significant positive correlation of the 
Global Index of Dependence on Estrogen (GIDE) scores for each pair of biopsies with percentage decrease in Ki67 immunohistochemistry (IHC) is 
shown. (b) Significant negative correlation of the GIDE score to the pretreatment expression of ERBB2, as derived from microarray profiling, is 
shown. Also shown are comparisons of the change in Ki67 immunohistochemistry (% decrease) is shown with pretreatment (c) ESR1 expression 
and (d) ERBB2 expression. Finally, comparisons of GIDE scores with pretreatment immunohistochemical measurements (Allred scores) are shown 
for (e) estrogen receptor (ER) and (f) progesterone receptor (PgR).Breast Cancer Research    Vol 9 No 3    Mackay et al.
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Table 1
Genes downregulated by AI treatment
ID Symbol Description Unigene Fold LFDR
HSI182A05 TFF1 Trefoil factor 1 (breast cancer, estrogen-inducible) Hs.162807 0.26 0.09
HSI054D07 HBB Haemoglobin, beta Hs.523443 0.31 0.00
HSI047B01 PDZK1 PDZ domain containing 1 Hs.444751 0.35 0.00
HSI035H02 CYP2B6 Cytochrome P450, family 2B6 Hs.1360 0.41 0.04
HSI075H09 AGR2 Anterior gradient 2 homolog (Xenopus laevis) Hs.530009 0.41 0.08
HSI031E07 STARD10 START domain containing 10 Hs.188606 0.42 0.00
HSI183G10 TFF3 Trefoil factor 3 (intestinal) Hs.82961 0.43 0.00
HSI147F09 ZBTB20 Zinc finger and BTB domain containing 20 Hs.570657 0.45 0.00
HSI182A08 STC2 Stanniocalcin 2 Hs.233160 0.47 0.00
HSI147F08 KTN1 Kinectin 1 (kinesin receptor) Hs.509414 0.47 0.00
HSI059H10 LOC143381 Hypothetical protein LOC143381 Hs.388347 0.47 0.00
HSI147F10 MSI2 Musashi homolog 2 (Drosophila) Hs.134470 0.49 0.00
HSI177G07 EST Transcribed locus Hs.443277 0.50 0.10
HSI053H02 UBE2C Ubiquitin-conjugating enzyme E2C Hs.93002 0.52 0.10
HSI096C06 MAPT Microtubule-associated protein tau Hs.101174 0.52 0.00
HSI049A02 ERGIC1 ER-golgi intermediate compartment 1 Hs.509163 0.53 0.09
HSI040C08 AZGP1 Alpha-2-glycoprotein 1, zinc Hs.546239 0.55 0.00
HSI133F06 EST Transcribed locus Hs.159264 0.55 0.00
HSI182E08 PLAT Plasminogen activator, tissue Hs.491582 0.55 0.00
HSI033B05 LY6E Lymphocyte antigen 6 complex, locus E Hs.521903 0.56 0.00
HSI048F12 CCND1 Cyclin D1 Hs.523852 0.56 0.10
HSI085G12 KCNK15 Potassium channel, subfamily K, member 15 Hs.528664 0.57 0.00
HSI177H07 PCBP3 Poly(rC) binding protein 3 Hs.474049 0.57 0.10
HSI032D02 ABCA3 ATP-binding cassette, subfamily A3 (ABC1) Hs.26630 0.57 0.00
HSI182A02 TFF3 Trefoil factor 3 (intestinal) Hs.82961 0.58 0.04
HSI025A03 FGD3 FYVE, RhoGEF and PH domain containing 3 Hs.411081 0.58 0.00
HSI070B06 AP1S1 Adaptor-related protein complex 1, sigma 1 subunit Hs.489365 0.58 0.08
HSI057H12 GNB2 Guanine nucleotide binding protein beta 2 Hs.185172 0.58 0.00
HSI080H11 SEMA3F Semaphorin 3F Hs.32981 0.59 0.00
HSI054G06 NUSAP1 Nucleolar and spindle associated protein 1 Hs.511093 0.59 0.00
HSI124D07 RIMS4 Regulating synaptic membrane exocytosis 4 Hs.517065 0.59 0.00
HSI065C09 CNNM2 Cyclin M2 Hs.500903 0.59 0.00
HSI080F02 PREX1 PIP3-dependent RAC exchanger 1 Hs.153310 0.59 0.00
HSI095H09 C6orf97 Chromosome 6 open reading frame 97 Hs.130239 0.59 0.00
HSI161G02 EST Transcribed locus Hs.570637 0.60 0.00
HSI045G02 UBE2T Ubiquitin-conjugating enzyme E2T (putative) Hs.5199 0.60 0.00
HSI046F10 TOP2A Topoisomerase (DNA) II alpha 170 kDa Hs.156346 0.60 0.00
HSI183D04 AR Androgen receptor Hs.496240 0.61 0.01
HSI183A08 SLC9A3R1 Solute carrier family 9, member 3 regulator 1 Hs.396783 0.61 0.00
HSI025G02 SHARPIN SHANK-associated RH domain interactor Hs.529755 0.61 0.08
Shown are the first 40 downregulated genes from a paired SAM analysis, which identified 1,264 genes to be downregulated by aromatase inhibitor (AI) treatment 
below a local false discovery rate of 1% (LFDR). The genes are ranked according to their fold change.Available online http://breast-cancer-research.com/content/9/3/R37
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Table 2
Genes upregulated by AI treatment
ID Symbol Description Unigene Fold LFDR
HSI022G08 LUM Lumican Hs.406475 2.87 0.11
HSI101E05 ODF2L Outer dense fiber of sperm tails 2-like Hs.149360 2.80 0.07
HSI027H04 IGJ Immunoglobulin J polypeptide Hs.381568 2.73 0.07
HSI082D05 RNH1 Ribonuclease/angiogenin inhibitor 1 Hs.530687 2.51 0.00
HSI056B04 COL3A1 Collagen, type III, alpha 1 Hs.443625 2.50 0.00
HSI182D05 MRC1L1 Mannose receptor, C type 1 Hs.461247 2.45 0.06
HSI067F08 C21orf70 Chromosome 21 open reading frame 70 Hs.410830 2.44 0.00
HSI127E04 CALD1 Caldesmon 1 Hs.490203 2.37 0.11
HSI030C06 PTPRC Protein tyrosine phosphatase, receptor type, C Hs.192039 2.36 0.11
HSI067H02 ASPN Asporin (LRR class 1) Hs.435655 2.34 0.00
HSI066B08 COL14A1 Collagen, type XIV, alpha 1 (undulin) Hs.409662 2.28 0.11
HSI049B12 COL1A2 Collagen, type I, alpha 2 Hs.489142 2.28 0.00
HSI049G07 DCN Decorin Hs.156316 2.28 0.00
HSI067E05 MRC1L1 Mannose receptor, C type 1 Hs.461247 2.22 0.05
HSI101D05 IFT122 Intraflagellar transport 122 homolog (Chlamydomonas) Hs.477537 2.17 0.03
HSI183E05 PDGFRA Platelet-derived growth factor receptor, alpha Hs.74615 2.14 0.09
HSI031A12 FSTL1 Follistatin-like 1 Hs.269512 2.12 0.00
HSI183H01 COL5A2 Collagen, type V, alpha 2 Hs.445827 2.11 0.00
HSI055A11 ECM2 Extracellular matrix protein 2 Hs.117060 2.08 0.09
HSI018G02 SPON1 Spondin 1, extracellular matrix protein Hs.445818 2.06 0.00
HSI183B01 PDGFRA Platelet-derived growth factor receptor, alpha Hs.74615 2.04 0.01
HSI037C02 CPVL Carboxypeptidase, vitellogenic-like Hs.233389 2.03 0.06
HSI062B08 SAS10 Disrupter of silencing 10 Hs.322901 2.01 0.00
HSI129E10 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) Hs.386283 2.00 0.00
HSI183G08 RGS1 Regulator of G-protein signalling 1 Hs.75256 1.98 0.18
HSI054F01 VIM Vimentin Hs.533317 1.97 0.00
HSI048C08 CTGF Connective tissue growth factor Hs.410037 1.97 0.00
HSI183G05 SPARC Secreted protein, acidic, cysteine-rich (osteonectin) Hs.111779 1.96 0.00
HSI139G09 ADAMTS2 ADAM metallopeptidase with thrombospondin motif 2 Hs.23871 1.96 0.00
HSI018D05 FBLN1 Fibulin 1 Hs.24601 1.95 0.00
HSI040E08 DUSP1 Dual specificity phosphatase 1 Hs.171695 1.95 0.00
HSI082C05 MAN1A1 Mannosidase, alpha, class 1A, member 1 Hs.102788 1.94 0.01
HSI098G12 RARRES1 Retinoic acid receptor responder 1 Hs.131269 1.94 0.00
HSI044C09 SAT Spermidine/spermine N1-acetyltransferase Hs.28491 1.92 0.09
HSI030F05 HTRA1 HtrA serine peptidase 1 Hs.501280 1.92 0.00
HSI088D11 CILP Cartilage intermediate layer protein Hs.442180 1.91 0.00
HSI040E09 MME Membrane metallo-endopeptidase (CALLA, CD10) Hs.307734 1.91 0.00
HSI028G12 PDGFRA Platelet-derived growth factor receptor, alpha Hs.74615 1.89 0.00
HSI060C05 FN1 Fibronectin 1 Hs.203717 1.89 0.00
HSI045G12 CXCL12 Chemokine ligand 12 (stromal cell-derived factor 1) Hs.522891 1.88 0.00
Shown are the first 40 upregulated genes from a paired SAM analysis, which identified 1,365 genes to be upregulated by aromatase inhibitor (AI) treatment below a 
local false discovery rate of 1% (LFDR). The genes are ranked according to their fold change.Breast Cancer Research    Vol 9 No 3    Mackay et al.
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Three clusters in this supervised analysis clearly represented
distinct pathway related phenotypes based upon the ontology
of the genes they contain (Figure 4). Genes in the 'proliferation
cluster' exhibited a highly significant overlap with a previously
characterized breast cancer proliferation signature [16]. We
labelled a cluster containing many genes known to be classi-
cally estrogen responsive in breast cancer as an 'estrogen
cluster' and one including collagens and other genes involved
in extracellular matrix (ECM) deposition as an 'ECM cluster'.
Figure 5a shows the combined effect of treatment on the
estrogen and proliferation metagenes (mean of each cluster's
M values) as a vector diagram in which the pretreatment and
post-treatment samples are joined by an arrow. Tumours with
extremely low baseline levels of estrogen-dependent gene
expression and HER2 amplified tumours exhibit very little
change in either cluster (for example, 39, 138 red arrows and
218, 216, 64, green dots, respectively). Perhaps most impor-
tantly, this analysis identified a number of cases that had major
reductions in expression of the estrogen metagene with mini-
mal impact on the proliferation metagene (for example, 145,
262, 263, blue arrows). Figure 5b shows the interaction of the
estrogen metagene and the ECM metagene. The ECM meta-
gene is clearly upregulated in the majority of biopsies irrespec-
tive of pretreatment levels of ESR1 and estrogen metagene
values (red arrows). The proliferation metagene exhibited the
highest positive correlation (r = 0.51, P = 0.000029) with the
change in Ki67 immunohistochemistry of any of the nine meta-
genes (for example, estrogen metagene: r = 0.31, P = 0.102).
Array profiling also identified sets of genes that were both pos-
itively and negatively correlated with ER in these biopsies. The
intersection of genes associated with ER and those identified
as estrogen responsive indicated that only 10% of the genes
most highly correlated with high ESR1  expression were
downregulated by estrogen deprivation in vivo. A complete list
of genes whose expression correlates with ESR1 with a Pear-
son correlation of greater or less than 0.5 is given in Additional
file 5.
Discussion
Anastrozole and letrozole are highly specific and efficient
inhibitors of the aromatase enzyme, leading to profound estro-
Figure 3
Expression changes in key index genes in response to AI treatment Expression changes in key index genes in response to AI treatment. Individual log ratio measurements are plotted and joined with a line in each of the 
paired biopsies. Individual results are shown for the downregulated genes PDZK1, TFF1, AGR2 and CCND1, and the upregulated genes DCN, 
LUM and ASPN. The percentage decrease in Ki67 immunohistochemistry (IHC) is shown in the bottom left panel for comparison.Available online http://breast-cancer-research.com/content/9/3/R37
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gen deprivation in postmenopausal women [17]. These agents
are also the most effective treatment for breast cancer in post-
menopausal patients and have become the standard of care
over recent years [2]. Here, we have used gene expression
profiling by microarray to identify the longitudinal differences in
gene expression between matched pretreatment and post-
treatment biopsies of tumours from patients treated with AIs.
The data generated in this study are biologically relevant in
terms of identifying genes that respond to estrogen withdrawal
in primary breast tumours in vivo, and are clinically relevant in
identifying genes or groups of genes that may be used to
understand and predict the response of patients to AI treat-
ment. Although many reports have examined estrogen-regu-
lated gene expression in breast cancer cells and model
systems, generating a comprehensive genome-wide cata-
logue of estrogen-responsive genes [18], there are as yet few
reported studies in which an AI was used as a biological probe
of estrogen-dependent expression profiles in human breast
carcinomas in vivo [19,20]. The number of patients included
in our study was too small for confidence in matters of detail,
but important broad messages may be developed.
Several studies have been reported over the past few years
utilizing expression profiling of breast tumours, which demon-
strated that the expression of ER by breast carcinomas is a
consistently dominant feature in their transcriptional profile
[13,21,22]. Although these studies have identified many hun-
dreds of genes that are significantly associated with ER
expression, it is has not been clear which of these genes are
directly responsible for estrogen responses in tumour cells.
Figure 4
Supervised clustering of pre and post treatment biopsies Supervised clustering of pre and post treatment biopsies. The 421 genes that best distinguished pretreatment and post-treatment biopsies were 
used to cluster the samples in the heatmap shown on the left. Three clusters of genes are shown in greater detail on the right: (a) a proliferation clus-
ter representing genes associated with proliferation and cell cycle progression, (b) an estrogen cluster of known highly estrogen-responsive genes 
and (c) an extracellular matrix (ECM) cluster of genes known to be involved in ECM remodelling.Breast Cancer Research    Vol 9 No 3    Mackay et al.
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The present study indicates that only a small proportion of the
genes correlating with ER status are estrogen-responsive in
vivo.
In the present study we included only ER-positive tumours
(plus three tumours with Allred scores of 2, conventionally
considered ER negative) [10]. Correlations between gene
expression and ER in the current dataset were therefore made
in relation to degree of ER expression rather than to ER posi-
tivity or negativity. Nonetheless, we observed strong correla-
tions between ER and many genes that have previously been
shown to be strongly associated with ER positivity, including
GATA3, FOXA1, AGR2, AR, and STC2, in microarray profiling
studies of mixed ER-positive and ER-negative tumours [21-
23]. The present study indicates that only a small proportion of
the genes correlating with ER status are estrogen responsive
in vivo.
The GIDE may be a useful approach to characterizing the over-
all biological reactivity of a tumour to and dependence on
estrogen. The data indicate that there is a continuum of such
dependence, with 3,304 genes changing in one tumour by
more than twofold over the 2-week treatment period, whereas
only 105 changed in another. These data recapitulate the con-
tinuum of change shown by Ki67 immunohistochemistry,
which indicates that almost all ER-positive tumours exhibit an
antiproliferative response to estrogen deprivation, although
this is highly variable between patients. The data from the
GIDE similarly suggest that few ER-positive tumours are com-
pletely nonresponsive to estrogen deprivation. There was only
a modestly significant relationship between the GIDE and the
pretreatment level of ER based on immunohistochemistry; the
current data suggest that high ER expression may be neces-
sary for a tumour to be highly responsive (high GIDE) but that
some tumours with a high ER have only a moderate or poor
biological response.
The GIDE may be a useful end-point for investigating the
mechanisms of resistance to hormonal therapy. One putative
mechanism is through over-expression of growth factor recep-
tors such as HER2. Although HER2 was associated with a low
GIDE, in all but one case these tumours also had low ER, as
has previously been observed [24]. PgR positivity has gener-
ally been regarded as indicative of an intact ER mechanism. An
association with a higher GIDE might have been anticipated,
and although there was a trend toward a positive association
with higher PgR expression, this was not significant, possibly
because of the limited numbers of samples. Although the
GIDE would benefit from a proven association with clinical
outcome, we recently showed that 2-week change in Ki67 was
predictive of long-term outcome after treatment with endo-
crine agents in the adjuvant setting [6,25,26], and in this study
the GIDE was found to be significantly associated with change
in Ki67. The profound changes in transcriptional profiles found
in some but not all tumours in this study suggest that it is pos-
sible that predicting clinical response to an AI by
transcriptional profiling may, as with Ki67, be more precise
when conducted in tumours shortly after starting treatment.
There have been many reports of the transcriptional profiling
of estrogen responses in breast cancer cell lines in vitro,
including those in MCF-7 [8,9], T47D [27] and ZR75.1 [28]
breast cancer cell lines and their derivatives [29,30], as well as
those using model systems in experimental animals [31,32].
These studies identified many hundreds of genes that were
upregulated and downregulated by estrogen treatments.
Figure 5
Vector diagrams of metagenes representing estrogen response, proliferation and ECM remodelling Vector diagrams of metagenes representing estrogen response, proliferation and ECM remodelling. Metagene values derived from the mean values 
of all the genes in each of the clusters in Figure 4 are plotted and connected with a line from dots (pretreatment values) to arrowheads (post-treat-
ment values). Estrogen metagene values are compared with the (a) proliferation metagene and (b) the extracellular matrix (ECM). The six biopsies 
with the lowest pretreatment estrogen metagene are coloured in red. The four biopsies with HER2 amplification and high ERBB2 expression are 
shown with green dots, and samples with the lowest responses in the proliferation metagene are highlighted in blue.Available online http://breast-cancer-research.com/content/9/3/R37
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Computational and experimental attempts have also been
made to integrate these data and catalogue all of the estrogen-
responsive genes and estrogen response elements in the
genome [18,33]. Many of the genes upregulated by estrogen
in vitro were downregulated by AI treatment in our study
including the majority of classically estrogen-responsive genes
(TFF1, TFF3, CYP2B6, PDZK1, and AGR2). TFF1 (pS2) is
one of the best characterized estrogen-responsive genes in
breast cancer [8,34-36]. CYP2B6 is dramatically upregulated
by estrogen in ZR75.1 cells, although it is not expressed in
MCF-7 cells [37]. PDZK1 has consistently been identified as
one of the genes most highly upregulated by oestradiol in
MCF-7 cells [8,9]. AGR2  is another classically estrogen-
responsive gene that is expressed in both cell lines and ER-
positive breast tumours [38] and that has been associated
with a poor response to hormonal therapy [39]. One of the
genes that we found to be significantly downregulated by AIs
was that encoding aromatase itself (CYP19A1). This finding
supports earlier evidence of a positive autocrine feedback
loop [40].
In contrast to the genes downregulated by AI treatment, the
upregulated genes are not represented by those that are
directly downregulated by estrogen in cell lines in vitro. Gene
Ontology analysis of the upregulated genes identified path-
ways involved with the regulation of the actin cytoskeleton,
cytokine-receptor interactions and focal adhesion to be more
commonly associated with the functions of stromal compo-
nents than of epithelial cells (VIM, CTGF, FN1, and SPARC).
The genes most highly upregulated by AI treatment include
several members of the of the small leucine-rich proteoglycan
family (LUM, ASPN, and DCN), which regulate matrix remod-
elling. Lumican is not expressed in cancer cells in breast can-
cers but in fibroblasts, and it is associated with high tumour
grade, low ER levels and young age [41]. Decorin is preferen-
tially expressed in stromal areas in proliferating endometrium,
is directly upregulated by estrogens in stromal endometrial
cells in vitro [42] and is upregulated in mouse uterus by estro-
gen treatment [43]. Asporin is closely related to biglycan,
which has been shown to be downregulated by estrogen in
the stroma of normal human breast tissue in a mouse xenograft
model [32]. The effect of this stromal signature on patient sur-
vival is unclear but reduced small leucine-rich proteoglycan
family expression has been observed in poor prognosis ER-
negative breast cancer [44].
There are several possible mechanisms for this upregulation of
a stromal signature clearing response to AI treatment. It was
notable that the genes representing this stromal signature
were upregulated independent of high level ER-α expression
in tumour cells. It is possible that upregulation may result from
an interaction with stromally expressed ER-β [45]. For
example, CD36 has been shown to be directly upregulated by
estrogen via ER-β [46], and both lumican and PDGFRA were
induced by the selective ER modulator raloxifene in U2OS
cells transfected with ER-β [30]. Among the other genes
upregulated by AI treatment in the present study are genes
representative of the normal profiles of luminal and myoepithe-
lial phenotypes [47,48] that are not driven by high-level ER
over-expression, including RARRES1, MME, TCF4, SFN, and
CAV1. This represents a joint upregulation in post-treatment
biopsies of a basal/stromal phenotype, which has also been
shown in estrogen treatments of normal human breast tissue
in xenograft studies [32].
Taken together, these findings highlight the fact that studies
identifying estrogen-responsive genes in cell lines do not take
into account the diversity of responsiveness, composition and
genetic backgrounds seen in primary ER-positive breast
tumours. Although many of the gene changes are likely to be
directly transcriptionally regulated by estrogen, it is also likely
that the majority are a secondary consequence of estrogen
deprivation and the resulting inhibition of breast tumour
proliferation by AI treatment. Recently, Oh and coworkers [38]
have attempted to integrate data on estrogen responsiveness
in MCF-7 cells in vitro with gene expression and clinical out-
come data from 65 ER-positive and/or PgR-positive breast
cancer patients to predict outcome for hormone responsive
breast cancer. The study used only the 383 genes that were
upregulated by estrogen treatment in this single cell line but, a
very high dose (1 μmol/l) of oestradiol was used and dosage
differences have been suggested to compromise compari-
sons of transcriptional signatures [49]. The identification of a
comprehensive profile of estrogen-responsive genes in
tumours deprived of estrogen in vivo may be expected to pro-
vide a much better basis on which to classify the estrogen
response of breast tumours than in vitro studies.
Robust gene selection methods were used to identify genes
that together best separated pretreatment from post-treatment
samples. Cluster analysis using these genes identified groups
associated with proliferation and estrogen responses. The 32
genes that constitute the 'proliferation cluster' contain 17 of
those reported by Dai and coworkers [16] as a proliferation
signature containing critical genes predicting the long-term
clinical outcome of patients with ER-positive breast tumours.
To summarize both the 'estrogen cluster' and the 'proliferation
cluster', we used metagene values to depict the relative
changes in tumour phenotype in response to AI treatment. In
most tumours there was a coordinated decrease in both of
these clusters, but we observed that in some tumours these
facets of phenotype change were uncoupled. A better under-
standing of the mechanisms that lead to a poor antiprolifera-
tive response in the presence of a good response in the
'estrogen cluster' of genes is likely to provide a guide to addi-
tional treatments for ER-positive breast cancer and may be
possible with an extension of this study to larger numbers of
tumours.Breast Cancer Research    Vol 9 No 3    Mackay et al.
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Conclusion
In summary, short-term estrogen deprivation with AIs leads to
profound changes in transcriptional profiles. Although many of
the genes were previously described in cell culture studies as
responsive to estrogen stimulation, many additional estrogen-
responsive genes were identified that responded to estrogen
deprivation in vivo, particularly those that are repressed by
estrogen. The study revealed complex changes in estrogen-
responsive pathways, proliferation and matrix remodelling,
which cannot be simply summarized by the ER status of the
tumours or completely recapitulated in cell line studies. The
global changes in gene expression can be integrated into a
GIDE that we found to be associated with previously estab-
lished correlates with clinical outcome. Studies of this type,
linked with clinical outcome, should enable the key genes that
underpin clinical response/benefit to be established and may
be expected to reveal the molecular features of tumours
responsible for sensitivity and resistance to estrogen
deprivation.
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